Düsseldorf, 5th November 2018 - FUJIFILM Europe is «Lead Sponsor» of the «FT Global Pharmaceutical and Biotechnology Conference 2018», Royal Lancaster London 5-6 November, as part of the global branding campaign «NEVER STOP».
A new marketing approach, which sees FUJIFILM at the forefront by spreading its point of view on the most disruptive issues that animate the Healthcare sector.
Active since 1936 into the Healthcare business, nowadays FUJIFILM covers the entire care pathways, with a patient-centric approach: prevention, diagnosis and treatment, and provides technologies and solutions which incorporates medical devices, pharmaceuticals, regenerative medicines, cosmetics and other products. Furthermore, FUJIFILM is developing AI technology to support diagnostic imaging, medical workflow, equipment warranty and service by expanding the AI technology under the “REiLI” brand. FUJIFILM's strategy is to use AI technology to harness the big data generated through the collection of medical and diagnostic information, working to develop and provide various products and services that can meet a diverse range of needs in clinical settings, contributing to even more efficient medical diagnosis and high quality medical treatment, leading to the maintenance and improvement of people's health.
The active participation with two top speakers to the discussion panels, wants to represent a moment of divulgation and sharing and to affirm the company as key player into the Healthcare panorama.
AGENDA: Tuesday 6th November, 2018
10:55 | Panel, PARTNERSHIP AND COLLABORATIONS: WHAT WORKS AND WHAT DOESN’T? Panelist: MARK DOUGLAS, Vice President, Strategic Business Development, FUJIFILM Diosynth Biotechnologies. |
16:00 | Panel, ENVISIONING THE FUTURE OF DIAGNOSTIC Panelist : KEVIN SHAH, Head of Enterprise New Business, FUJIFILM Medical Systems Europe |
The “NEVER STOP” global branding campaign, started on 15th October, aims to highlight FUJIFILM’s firm and unwavering commitment to achieving continued corporate growth and never stop building on our innovations and expertise.